A Study of LY4175408 in Participants With Advanced Cancer
← catalyst calendarNCT07046923 · readout ≤ 1,442 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
240estimated
Sites
27
Countries
China, France, Japan +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-28 | actual | When the study began enrolling |
| Primary completion | Jul 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Carcinoma, Non-Small-Cell Lung
- Small Cell Lung Carcinoma
- Endometrial Neoplasms
- Neoplasm Metastasis
- Triple Negative Breast Cancer
Interventions
- Drug: LY4175408
- Drug: Pembrolizumab
- Drug: Carboplatin
- Drug: Cisplatin
Primary outcomes
what the primary-completion date above is the date OFPhase 1a-Number of Participants with Dose Limiting Toxicities of LY4175408
measured 1 Cycle (21 days)
Phase 1b-Overall Response Rate (ORR): Percentage of Participants with Best Response of Complete Response (CR) or Partial Response (PR)
measured Baseline up to approximately 4 years
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed